ArticleScientific reports2021
Preparation of serum capped silver nanoparticles for selective killing of microbial cells sparing host cells.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 20 citations in OpenAlex.
- Biogenic Silver Nanoparticles from the Cell-Free Supernatant of Mychonastes sp. B1: Antibacterial and Antibiofilm Effects, and Wound Healing Activity Supported by Gene and Protein Expression Analysis.Molecular biotechnology · 2026Article
- Engineering "Yin-Yang" Ag/AgCl-Polymer Nanotherapeutic for Tunable Silver Ion Release With Improved In Vivo Biocompatibility and Antimicrobial Potency.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- The Role of Silver and Silver-Based Products in Wound Management: A Review of Advances and Current Landscape.Journal of functional biomaterials · 2026Review
- A Preliminary in-vitro Evaluation of Serum Capped Colloidal Silver Nanoparticles on Liver Cancer towards Development of Safe Personalized Nanomedicine.International journal of nanomedicine · 2026Article
- Silver Nanoparticles: A Versatile Tool Against Infectious and Non-Infectious Diseases.Antibiotics (Basel, Switzerland) · 2025Review
- Unlocking the Potential of Silver Nanoparticles: From Synthesis to Versatile Bio-Applications.Pharmaceutics · 2024Review
- An effective antibiofilm strategy based on bacteriophages armed with silver nanoparticles.Scientific reports · 2024Article
- Lycopene attenuates silver nanoparticle-induced liver injury in albino mice.Journal of biochemical and molecular toxicology · 2023Article
- Antibacterial Effect of Silver Nanoparticles Is Stronger If the Production Host and the Targeted Pathogen Are Closely Related.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following access into the cell, colloidal silver nanoparticles exhibit generalized cytotoxic properties, thus appear as omnipotent microbicidal, but not suitable for systemic use unless are free of toxic effects on host cells. The AgNP-Serum-18 when prepared from silver nitrate, using dextrose as reducing and group-matched homologous serum as a stabilizing agent, selective endocytosis, and oxidative stress-dependent bio-functional damages to the host are mostly eliminated. For their bio-mimicking outer coat, there is the least possibility of internalization into host cells or liberation of excess oxidants in circulation following interaction with erythrocytes or vascular endothelial cells. The presence of infection-specific antibodies in the serum can make such nano-conjugates more selective. A potent antimicrobial action and a wide margin of safety for mammalian cells in comparison with very similar PVA-capped silver nanoparticles have been demonstrated by the in-vitro challenge of such nanoparticles on different microbes, human liver cell-line, and in-vivo study on mice model. This may open up wide-range therapeutic prospects of colloidal nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.